Patients’ worries before starting antiretroviral therapy and their association with treatment adherence and outcomes: a prospective study in rural Uganda, 2004 - 2009

BMC Research Notes

Joseph O Mugisha¹  Rosemary Lubega¹  Harriet Namugenyi¹  Kenneth Ekoru¹  Billy N Mayanja¹ 

[1] MRC/UVRI Uganda Research Unit on AIDS, P.O. Box 49, Entebbe, Uganda

关键词: Treatment outcomes;    Adherence;    Patients’ worries;    Antiretroviral therapy;   

Others  :  1142708
DOI  :  10.1186/1756-0500-6-187

 received in 2012-10-23, accepted in 2013-04-24,  发布年份 2013

【 摘 要 】

Background

In HIV-infected persons, good adherence to antiretroviral therapy (ART) is essential for successful treatment outcomes. Patients’ worries before starting ART may affect their ART adherence and treatment outcomes.

Methods

Between 2004 and 2009, HIV-infected individuals in a prospective cohort study in rural Uganda were assessed for ART eligibility. A counsellor explained the ART eligibility criteria, adherence and side effects, and recorded the patients’ worries related to ART. Every quarter, patients who initiated ART had clinical, immunological (CD4 cell counts) and virological (viral loads) assessments, and data were collected on ART adherence using patients’ self-reports and pill counts. We describe the patients’ worries and examine their association with ART adherence, and immunological and virological outcomes.

Results

We assessed 421 patients, 271 (64%) were females, 318 (76%) were aged 30 years and above and 315 (75%) were eligible for ART. 277 (66%) reported any worry, and the proportions were similar by sex, age group and ART eligibility status. The baseline median CD4 counts and viral loads were similar among patients with any worry and those with no worry. The commonest worries were: fear of HIV serostatus disclosure; among 69 (16%) participants, lack of food when appetite improved after starting ART; 50 (12%), concurrent use of other medications; 33 (8%), adherence to ART; 28 (7%) and problems concerning condom use; 27 (6%). After 24 months or more on ART, patients who reported any worry had made more scheduled ART refill visits than patients who reported no worry (p<0.01), but the annual CD4 cell increases were similar (p=0.12). After one year on ART, patients who reported any worry had greater virological suppression than patients who reported no worry (p<0.05).

Conclusions

Despite the lack of significant associations of worries with unfavourable ART outcomes, physicians and counsellors should assist patients in overcoming their worries that can cause stress and discomfort. Food supplements may be desirable for some patients initiating ART.

【 授权许可】

   
2013 Mayanja et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Conway B: The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007, 45(Suppl 1):S14-S18.
• [2]Mermin J: Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008, 371(9614):752-759.
• [3]Mocroft A: Decline in the AIDS Mortality and death rates in the Eurosida study: An observational study. Lancet 2003, 362(9377):22-29.
• [4]Dlamini PS: HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS 2009, 23(5):377-387.
• [5]Wanyama J: Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda. AIDS 2007, 21(11):1486-1487.
• [6]Byakika-Tusiime J: Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 2005, 16(1):38-41.
• [7]Eholie SP: Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d’Ivoire. J Acquir Immune Defic Syndr 2007, 45(3):355-358.
• [8]Iliyasu Z: Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano. Nigeria. Niger J Med 2005, 14(3):290-294.
• [9]Crane JT: The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala. Uganda. AIDS Behav 2006, 10(4):437-442.
• [10]Mills EJ: Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006, 3(11):e438.
• [11]Stenson AL: Evaluation of antiretroviral therapy (ART)-related counselling in a workplace-based ART implementation programme. South Africa. AIDS Care 2005, 17(8):949-957.
• [12]Tuldra A, Wu AW: Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31(Suppl 3):S154-S157.
• [13]Morgan D: An HIV-1 natural history cohort and survival times in rural Uganda. AIDS 1997, 11(5):633-640.
• [14]Mulder DW: HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort. AIDS 1994, 8(1):87-92.
• [15]Mbulaiteye SM: Generalizability of population-based studies on AIDS: a comparison of newly and continuously surveyed villages in rural southwest Uganda. Int J Epidemiol 2002, 31(5):961-967.
• [16]World Health Organization: Clinical staging of HIV infection. Geneva: WHO; 1990.
• [17]Ministry of Health and Republic of Uganda: National Policy Guidelines for cotrimoxazole prophylaxis for people with HIV/AIDS. Kampala, Uganda: Earnest Publishers; 2005.
• [18]Ministry of Health and Republic of Uganda: National Antiretroviral Treatment and Care Guidelines for Adults and Children. Kampala, Uganda: Earnest Publishers; 2003.
• [19]Ministry of Health and Republic of Uganda: National Antiretroviral Treatment and Care Guidelines for Adults and Children. Kampala, Uganda: Earnest Publishers; 2008.
• [20]Cinti SK: Adherence to antiretrovirals in HIV disease. AIDS Read 2000, 10(12):709-717.
• [21]Hecht FM: Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998, 10(8):57-59.
• [22]Stirratt MJ: The role of HIV serostatus disclosure in antiretroviral medication adherence. AIDS Behav 2006, 10(5):483-493.
• [23]Waddell EN, Messeri PA: Social support, disclosure, and use of antiretroviral therapy. AIDS Behav 2006, 10(3):263-272.
• [24]Medley A: Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull World Health Organ 2004, 82(4):299-307.
• [25]King R: Processes and outcomes of HIV serostatus disclosure to sexual partners among people living with HIV in Uganda. AIDS Behav 2008, 12(2):232-243.
• [26]Deribe K: Disclosure experience and associated factors among HIV positive men and women clinical service users in Southwest Ethiopia. BMC Publ Health 2008, 8:81. BioMed Central Full Text
• [27]Au JT: Access to adequate nutrition is a major potential obstacle to antiretroviral adherence among HIV-infected individuals in Rwanda. AIDS 2006, 20(16):2116-2118.
• [28]Mills E: African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J 2005, 4:19. BioMed Central Full Text
• [29]Namuddu B: Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda. BMC Publ Health 2011, 11:855. BioMed Central Full Text
• [30]Peltzer K: Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in Kwazulu-Natal, South Africa. Afr J Tradit Complement Altern Med 2010, 7(2):125-137.
• [31]Langlois-Klassen D: Use of traditional herbal medicine by AIDS patients in Kabarole District, western Uganda. Am J Trop Med Hyg 2007, 77(4):757-763.
• [32]Babb DA: Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med 2007, 12(3):314-320.
• [33]Bunnell R: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006, 20(1):85-92.